Stay updated with breaking news from Small Cell Lung. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
1. The 18-month event-free survival in the perioperative nivolumab group was 70.2% vs 50.0% in the chemotherapy group with HR 0.58 (significant). 2. Grade 3-4 treatment-related adverse events occurred in 32.5% in the nivolumab group vs 25.2% in the chemotherapy group. Evidence Rating Level: 1 (Excellent) Study Rundown: Nivolumab, an anti-PD-1 antibody, combined with chemotherapy,
Breakthrough DLL3-Targeting Therapy Regimen for a Major Solid Tumor
/PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved IMDELLTRA™ (tarlatamab-dlle) for the...
A 76% lower risk was displayed with adjuvant alectinib compared to chemotherapy treatment for non–small cell lung cancer.
Approval based on Phase III ALINA study showing Alecensa reduced the risk of disease recurrence or death by an unprecedented 76% in people with ALK-positive early-stage resected non-small cell lung...